Advertisement

Reactions Weekly

, Volume 1729, Issue 1, pp 96–96 | Cite as

Daratumumab/rituximab

Depletion of B cells and plasma cells: 3 case reports
Case report
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a case series of three patients (1 male and 2 females) aged between 20 months to 19 years developed depletion of B cells and plasma cells following administration of rituximab and daratumumab [durations of treatments to reactions onsets not stated; not all routes, dosages and outcomes stated]. Subsequently, the 19-year-old woman died due to refractory autoimmune haemolytic anaemia (AIHA).

Patient 1: A 19-year-old woman had pre-B-cell acute lymphoblastic leukemia (B-ALL) with positive minimal residual disease (MRD). She underwent myeloablative haematopoietic stem cell transplantation (HSCT) from a matched unrelated donor (MUD) following conditioning with busulphan, fludarabine, clofarabine and alemtuzumab. Four months (116 days) following the HSCT, and one month after a second...

Reference

  1. Schuetz C, et al. Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. Blood Advances 2: 2550-2553, No. 19, 9 Oct 2018. Available from: URL: http://doi.org/10.1182/bloodadvances.2018020883 - GermanyPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations